Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) issued its quarterly earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.21), Zacks reports.

Eupraxia Pharmaceuticals Stock Down 6.6%

EPRX opened at $7.10 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $9.32. The company has a 50-day simple moving average of $8.26 and a 200 day simple moving average of $6.89. The stock has a market capitalization of $255.32 million, a price-to-earnings ratio of -6.89 and a beta of 1.27.

Key Headlines Impacting Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $11 price target, which provides upside support for the stock despite the earnings cuts — MarketBeat EPRX Coverage
• Neutral Sentiment: Brokers published predictions ahead of EPRX’s Q2 earnings, adding near-term expectations but not reporting any definitive catalyst; this keeps near-term guidance uncertainty elevated. Brokers Offer Predictions for EPRX Q2 Earnings
• Neutral Sentiment: A short-interest report in the period shows effectively zero reported short interest (data appears anomalous), so short covering is unlikely to be a near-term price driver.
• Negative Sentiment: Zacks downgraded Eupraxia from “Hold” to “Strong Sell,” a formal negative signal that likely pressured the shares. Zacks Downgrade
• Negative Sentiment: HC Wainwright cut multiple near- and multi‑year EPS forecasts (FY2026–FY2029 and Q1/Q3 2026), materially lowering profitability outlooks even while keeping a Buy rating — this mix of lower forecasts and unchanged optimism may create investor skepticism. HC Wainwright Estimates
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS forecast (now deeper negative), which adds to the consensus downside revisions despite Lifesci retaining a “Strong-Buy” stance.

Analyst Ratings Changes

A number of research firms have commented on EPRX. HC Wainwright reduced their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday. Zacks Research lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Cantor Fitzgerald lifted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Finally, Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $7,965,000. Ikarian Capital LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $4,606,000. Squadron Capital Management LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $3,775,000. Velan Capital Investment Management LP acquired a new position in Eupraxia Pharmaceuticals during the third quarter valued at approximately $2,077,000. Finally, Alyeska Investment Group L.P. bought a new stake in Eupraxia Pharmaceuticals during the third quarter worth $1,475,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.